SILAC-based proteomic analysis reveals that salidroside antagonizes cobalt chloride-induced hypoxic effects by restoring the tricarboxylic acid cycle in cardiomyocytes

Xu, Zhongwei; Chen, Xi; Jin, Xiaojuan; Meng, Xiangyan; Zhou, Xin; Fan, Fengxu; Mao, Shi‐Yun; Wang, Yue; Zhang, Wencheng; Shan, Nana; Li, Yuming; Xu, Rui‐hua

doi:10.1016/j.jprot.2015.09.028

Cited by 40 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further asked if amelioration of hypoxia affects myopia progression. The FD eyes of guinea pigs were given periocular injections of the antihypoxic drugs salidroside (31) or formononetin (32). After the injection of salidroside (10 μg per eye) or formononetin (5.0 μg per eye) for 4 wk, the scleral levels of HIF-1α, COL1α1, and α-SMA were determined by Western blot ( Fig.…”

Section: Antihypoxia Drugs Inhibited the Progression Of Experimental mentioning

confidence: 99%

“…Salidroside helps the body adapt to and resist stress (52) and has protective effects in vivo for hypoxia-induced cardiac apoptosis (53) and hypoxiainduced pulmonary hypertension (54). It antagonizes cobalt chloride-induced hypoxic effects in vitro (31,55). Formononetin has a protective effect on hypoxia-induced retinal neovascularization (32) and, like salidroside, it also antagonizes cobalt chloride-induced hypoxic effects in vitro (56).…”

Section: Antihypoxic Treatment Offers Therapeutic Strategies For Myopiamentioning

confidence: 99%

See 1 more Smart Citation

Scleral hypoxia is a target for myopia control

Chen

Zhao

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

266

233

View full text Add to dashboard Cite

Worldwide, myopia is the leading cause of visual impairment. It results from inappropriate extension of the ocular axis and concomitant declines in scleral strength and thickness caused by extracellular matrix (ECM) remodeling. However, the identities of the initiators and signaling pathways that induce scleral ECM remodeling in myopia are unknown. Here, we used single-cell RNA-sequencing to identify pathways activated in the sclera during myopia development. We found that the hypoxia-signaling, the eIF2-signaling, and mTOR-signaling pathways were activated in murine myopic sclera. Consistent with the role of hypoxic pathways in mouse model of myopia, nearly one third of human myopia risk genes from the genome-wide association study and linkage analyses interact with genes in the hypoxia-inducible factor-1α (HIF-1α)-signaling pathway. Furthermore, experimental myopia selectively induced HIF-1α up-regulation in the myopic sclera of both mice and guinea pigs. Additionally, hypoxia exposure (5% O) promoted myofibroblast transdifferentiation with down-regulation of type I collagen in human scleral fibroblasts. Importantly, the antihypoxia drugs salidroside and formononetin down-regulated HIF-1α expression as well as the phosphorylation levels of eIF2α and mTOR, slowing experimental myopia progression without affecting normal ocular growth in guinea pigs. Furthermore, eIF2α phosphorylation inhibition suppressed experimental myopia, whereas mTOR phosphorylation induced myopia in normal mice. Collectively, these findings defined an essential role of hypoxia in scleral ECM remodeling and myopia development, suggesting a therapeutic approach to control myopia by ameliorating hypoxia.

show abstract

Section: Antihypoxia Drugs Inhibited the Progression Of Experimental mentioning

confidence: 99%

Section: Antihypoxic Treatment Offers Therapeutic Strategies For Myopiamentioning

confidence: 99%

Scleral hypoxia is a target for myopia control

Chen

Zhao

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

266

233

View full text Add to dashboard Cite

show abstract

“…Drugs such as salidroside and formononetin have been known to exhibit anti-hypoxic effects in cardiac myocytes, which may hold great potential to treat scleral hypoxia in myopia. 141,142 Salidroside has a protective effect for hypoxia-induced cardiac apoptosis and pulmonary hypertension. 143,144 In cardiac myocytes, the extrinsic apoptotic pathway occurs though the binding of the death receptor Fas and FasL, which initiates a pathway of cytosolic death through aggregation of Fas-Associated Death Domain (FADD) adaptor protein and activation of caspase 8.…”

Section: Anti-hypoxia Drugsmentioning

confidence: 99%

<p>Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia</p>

Pugazhendhi¹,

Ambati²,

Hunter³

2020

OPTH

View full text Add to dashboard Cite

Purpose: This review discusses the etiology and pathogenesis of myopia, prevention of disease progression and worsening axial elongation, and emerging myopia treatment modalities. Introduction: Pediatric myopia is a public health concern that impacts young children worldwide and is associated with numerous future ocular diseases such as cataract, glaucoma, retinal detachment and other chorioretinal abnormalities. While the exact mechanism of myopia of the human eye remains obscure, several studies have reported on the role of environmental and genetic factors in the disease development.Methods: A review of literature was conducted. PubMed and Medline were searched for combinations and derivatives of the keywords including, but not limited to, "pediatric myopia", "axial elongation", "scleral remodeling" or "atropine." The PubMed and Medline database search were performed for randomized control trials, systematic reviews and metaanalyses using the same keyword combinations. Results: Studies have reported that detection of genetic correlations and modification of environmental influences may have a significant impact in myopia progression, axial elongation and future myopic ocular complications. The conventional pharmacotherapy of pediatric myopia addresses the improvement in visual acuity and prevention of amblyopia but does not affect axial elongation or myopia progression. Several studies have published varying treatments, including optical, pharmacological and surgical management, which show great promise for a more precise control of myopia and preservation of ocular health. Discussion: Understanding the role of factors influencing the onset and progression of pediatric myopia will facilitate the development of successful treatments, reduction of disease burden, arrest of progression and improvement in future of the management of myopia.

show abstract

“…Anti-hypoxic drugs such as salidroside and formononetin have shown antihypoxic effects to treat scleral hypoxia in myopia [53,54]. Scleral hypoxia, which is induced by Hypoxia-Inducible Factor-1α (HIF-1), triggers a signaling cascade for myofibroblast trans-differentiation leading to scleral extracellular collagenous matrix remodeling in progressing myopia [55].…”

Section: Anti-hypoxic Drugsmentioning

confidence: 99%

Reduction of Myopia Burden and Progression

Pugazhendhi¹,

Ambati²,

Hunter³

2020

Intraocular Lens

View full text Add to dashboard Cite

Myopia is a significant worldwide public health concern, and its prevalence is drastically increasing in recent years. It was once viewed as a benign refractive error, but is now one of the leading causes of blindness and is associated with numerous ocular diseases, which makes it crucial to develop viable treatment options to adequately correct the refractive error and to halt the disease progression. The treatment of myopia can be classified into three groups: optical, pharmacological, and surgical management, which are aimed at adjusting to the refractive error and reducing the axial elongation. The conventional treatment modalities for myopia, such as single vision glasses, correct the refractive error and improve visual quality of life, but do not affect myopia progression or axial elongation. The newer and various myopic interventions including spectacle corrections, contact lens corrections, pharmacological treatments and surgical corrections, hold great potential for adequate disease control to improve the quality of life, reduce myopia burden, and preserve the ocular health.

show abstract

SILAC-based proteomic analysis reveals that salidroside antagonizes cobalt chloride-induced hypoxic effects by restoring the tricarboxylic acid cycle in cardiomyocytes

Cited by 40 publications

References 42 publications

Scleral hypoxia is a target for myopia control

Scleral hypoxia is a target for myopia control

<p>Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia</p>

Reduction of Myopia Burden and Progression

Contact Info

Product

Resources

About